经导管二尖瓣缘对缘修复领域的十大未来挑战。
Ten Future Challenges in the Field of Transcatheter Mitral Valve Edge-to-Edge Repair.
作者信息
Orban Mathias, Weckbach Ludwig T, Stocker Thomas J, Doldi Philipp M, Näbauer Michael, Massberg Steffen, Hausleiter Jörg, Stolz Lukas
机构信息
Medizinische Klinik und Poliklinik I, LMU Klinikum, Marchioninistraße 15, 81377 Munich, Germany.
German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, 81377 Munich, Germany.
出版信息
J Clin Med. 2024 Mar 21;13(6):1799. doi: 10.3390/jcm13061799.
Abstract
Mitral valve transcatheter edge-to-edge repair (M-TEER) and replacement (TMVR) have evolved as guideline-recommended treatment approaches for mitral regurgitation (MR). Even though they are supported by a growing body of evidence from either randomized trials or large registries, there are still several unsolved challenges in the field of interventional MR treatment. In the present review, we discuss the ten most important open questions regarding M-TEER and TMVR.
摘要
二尖瓣经导管缘对缘修复术（M-TEER）和置换术（TMVR）已发展成为二尖瓣反流（MR）的指南推荐治疗方法。尽管它们得到了来自随机试验或大型注册研究的越来越多证据的支持，但在介入性MR治疗领域仍存在一些未解决的挑战。在本综述中，我们讨论了关于M-TEER和TMVR的十个最重要的悬而未决的问题。
相似文献
1
Ten Future Challenges in the Field of Transcatheter Mitral Valve Edge-to-Edge Repair.
J Clin Med. 2024 Mar 21;13(6):1799. doi: 10.3390/jcm13061799.
2
Transcatheter mitral valve replacement or repair for secondary mitral regurgitation: a propensity score-matched analysis.
Eur J Heart Fail. 2023 Mar;25(3):399-410. doi: 10.1002/ejhf.2797. Epub 2023 Mar 8.
3
Outcomes of COMBO therapy for severe mitral regurgitation compared with transcatheter edge-to-edge repair.
Front Cardiovasc Med. 2024 Feb 26;11:1223588. doi: 10.3389/fcvm.2024.1223588. eCollection 2024.
4
Transcatheter edge-to-edge mitral valve repair in mitral regurgitation: current status and future prospects.
Expert Rev Med Devices. 2023 Feb;20(2):99-108. doi: 10.1080/17434440.2022.2098013. Epub 2022 Jul 20.
5
Thirty-day and one-year outcomes following transcatheter mitral valve edge-to-edge repair versus transapical mitral valve replacement in patients with left ventricular dysfunction.
AsiaIntervention. 2023 Mar 15;9(1):78-86. doi: 10.4244/AIJ-D-22-00049. eCollection 2023 Mar.
6
Randomized Trials Are Needed for Transcatheter Mitral Valve Replacement.
JACC Cardiovasc Interv. 2021 Sep 27;14(18):2039-2046. doi: 10.1016/j.jcin.2021.06.014.
7
Transcatheter Mitral Valve Replacement Using Transcatheter Aortic Valve or Dedicated Devices: Current Evidence and Future Prospects.
J Clin Med. 2023 Oct 24;12(21):6712. doi: 10.3390/jcm12216712.
8
Mitral valve transcatheter edge-to-edge repair.
EuroIntervention. 2023 Jan 23;18(12):957-976. doi: 10.4244/EIJ-D-22-00725.
9
Clinical Impact of Tricuspid Regurgitation on Transcatheter Edge-to-Edge Mitral Valve Repair for Mitral Regurgitation.
Cardiovasc Revasc Med. 2022 Aug;41:1-9. doi: 10.1016/j.carrev.2022.01.027. Epub 2022 Feb 5.
10
Combined Tricuspid and Mitral Versus Isolated Mitral Valve Repair for Severe MR and TR: An Analysis From the TriValve and TRAMI Registries.
JACC Cardiovasc Interv. 2020 Mar 9;13(5):543-550. doi: 10.1016/j.jcin.2019.10.023. Epub 2020 Jan 15.
本文引用的文献
1
Transcatheter mitral valve replacement at an inflection point: lessons learned and the path forward.
Eur Heart J. 2024 May 27;45(20):1776-1778. doi: 10.1093/eurheartj/ehae013.
2
Artificial intelligence-derived risk score for mortality in secondary mitral regurgitation treated by transcatheter edge-to-edge repair: the EuroSMR risk score.
Eur Heart J. 2024 Mar 14;45(11):922-936. doi: 10.1093/eurheartj/ehad871.
3
Applying the TRILUMINATE Eligibility Criteria to Real-World Patients Receiving Tricuspid Valve Transcatheter Edge-to-Edge Repair.
JACC Cardiovasc Interv. 2024 Feb 26;17(4):535-548. doi: 10.1016/j.jcin.2023.11.014. Epub 2023 Nov 20.
4
Transcatheter Edge-to-Edge Repair in 5,000 Patients With Secondary Mitral Regurgitation: COAPT Post-Approval Study.
J Am Coll Cardiol. 2023 Sep 26;82(13):1281-1297. doi: 10.1016/j.jacc.2023.07.015.
5
Extracorporeal Life Support in Infarct-Related Cardiogenic Shock.
N Engl J Med. 2023 Oct 5;389(14):1286-1297. doi: 10.1056/NEJMoa2307227. Epub 2023 Aug 26.
6
Heart failure medical therapy prior to mitral transcatheter edge-to-edge repair: the STS/ACC Transcatheter Valve Therapy Registry.
Eur Heart J. 2023 Nov 21;44(44):4650-4661. doi: 10.1093/eurheartj/ehad584.
7
2-year outcomes of MitraClip as a bridge to heart transplantation: The international MitraBridge registry.
Int J Cardiol. 2023 Nov 1;390:131139. doi: 10.1016/j.ijcard.2023.131139. Epub 2023 Jun 23.
8
Guideline-Directed Medical Therapy Tolerability in Patients With Heart Failure and Mitral Regurgitation: The COAPT Trial.
JACC Heart Fail. 2023 Jul;11(7):791-805. doi: 10.1016/j.jchf.2023.03.009. Epub 2023 Apr 26.
9
Impact of Transcatheter Edge-to-Edge Mitral Valve Repair on Guideline-Directed Medical Therapy Uptitration.
JACC Cardiovasc Interv. 2023 Apr 24;16(8):896-905. doi: 10.1016/j.jcin.2023.01.362. Epub 2023 Mar 22.
10
Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials.
J Card Fail. 2023 Jul;29(7):1107-1109. doi: 10.1016/j.cardfail.2023.03.017. Epub 2023 Apr 5.
Zotero 插件